AUG 2 2 2005

Jal

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

BADDING THE PADELWOIK REGULATION ACTOR 1885. HE	Application Number	10/766,122
TRANSMITTAL	Filing Date	January 27, 2004
FORM	First Named Inventor	Hoffmann et al.
(to be used for all correspondence after initial filin	Art Unit	1624
(to be used for all correspondence area minds min	Examiner Name	Kahsay, H., Ph.D.
	Attorney Docket Number	
Total Number of Pages in This Submission	Automory Booker Names	21558 US
ENCLOSURES (Check all that apply)		
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks -Response to F	After Allowance communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Restriction Requirement
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name Kimberly J. Prior ,		
Date 8/19/2005		
CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name Kimberly J. Prior		
Signature Xmb	a legtrear	Date 8/19/2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors:

Hoffmann et al.

Group: 1624

Examiner: Kahsay, H., Ph.D.

Serial No. 10/766,122, filed January 27, 2004

(Ref. No. 21558 US)

For: NEW CRYSTALLINE MODIFICATIONS OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ⁶-THIOMORPHOLIN-4-YL)-4-(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE

RESPONSE TO RESTRICTION REQUIREMENT

Nutley, New Jersey 07110 Date: August 19, 2005

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This election is filed in response to the Restriction Requirement issued August 1, 2005, in connection with the above-identified patent application. A response to this Office Action is due September 1, 2005. Applicants respectfully request consideration of the following remarks.

Claims 1 to 30 are pending. The claims have been restricted to the following two groups.

- I. Claims 1 to 15 and 28 to 30, drawn to crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1λ⁶-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, composition and process of making, classified in class 544, subclass 58.2.
- II. Claims 16 to 27, drawn to a method of treating central nervous system disorders, classified in class 514, various subclasses.